Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis
Konstantinos Savvatis,Irene Müller,Matthias Fröhlich,Kathleen Pappritz,Christin Zietsch,Nazha Hamdani,Karsten Grote,Bernhard Schieffer,Karin Klingel,Sophie Van Linthout,Wolfgang A. Linke,Heinz-Peter Schultheiss,Carsten Tschöpe
DOI: https://doi.org/10.1007/s00395-014-0449-2
IF: 12.416
2014-10-25
Basic Research in Cardiology
Abstract:Increased levels of interleukin-6 (IL-6) have been observed in patients with acute myocarditis and are associated with poor prognosis. This study was designed to examine whether treatment with anti-IL-6 receptor antibody improves cardiac dysfunction and left ventricular (LV) remodeling in experimental Coxsackie virus B3 (CVB3)-induced myocarditis. C57BL6/J mice were subjected to acute CVB3 infection. One day after viral infection mice were treated with a single injection of an anti-IL-6 receptor antibody (MR16-1, tocilizumab) or control IgG. Seven days after viral infection, LV function was examined by conductance catheter technique, cardiac remodeling assessed by estimation of titin phosphorylation, cardiac fibrosis, and inflammatory and antiviral response by immunohistochemistry, RT-PCR and cell culture experiments. Compared to controls, infected mice displayed an impaired systolic and diastolic LV function associated with an increase in cardiac inflammation, fibrosis and impaired titin phosphorylation. IL-6 receptor blockade led to a shift of the immune response to a Th1 direction and significant reduction of viral load. In addition, cardiac immune response, extracellular matrix regulation and titin function improved, resulting in a preserved LV function. IL-6 receptor blockade exerts cardiac beneficial effects by antiviral and immunomodulatory actions after induction of an acute murine CVB3 virus myocarditis.
cardiac & cardiovascular systems